Brief: IBio Initiates Non-Human Primate Study Of First-In-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention In Weight Regain After GLP-1 Treatment
16/06/2025 12:45
June 16 (Reuters) - iBio Inc IBIO.O: IBIO INITIATES NON-HUMAN PRIMATE STUDY OF FIRST-IN-CLASS ACTIVIN E ANTIBODY FOLLOWING POSITIVE PRECLINICAL DATA DEMONSTRATING PREVENTION IN WEIGHT REGAIN AFTER GLP-1 TREATMENT IBIO INC - IBIO-610 DRIVES 8.9% BODY WEIGHT LOSS IN MICE IBIO INC - PRECLINICAL RESULTS SHOW 26% FAT REDUCTION WITH IBIO-610 IBIO INC - IBIO-610 PREVENTS WEIGHT REGAIN IN MICE AFTER GLP-1 THERAPY Source text: ID:nGNXwP591 Further company coverage: IBIO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on iBio
See all newsBrief: iBio - IBIO-610 Plus Semaglutide Preserves Lean Mass In Eight-Week Obese NHP Study
Brief: Ibio Reports Fiscal Year 2026 Financial Results And Provides Corporate Update
Brief: Ibio Reports Q3 Fiscal Year 2026 Financial Results And Provides Corporate Update
U.S. STOCKS ON THE MOVE-Meta, Legence, Chegg
U.S. STOCKS ON THE MOVE-Hims & Hers, Chewy, Longeveron